Please join us for a discussion among leading capital markets professionals from the London Stock Exchange, Stifel and Goodwin on how the UK IPO process differs from a U.S. listing and offers flexibility. The panel will be joined by special guest Erik Lium, PhD, Chief Commercial Innovation Officer of the Mount Sinai Health System in New York, who will discuss Mount Sinai’s role in the London listings of four U.S.-based healthcare and life sciences businesses since 2018 and give a first-hand account on the reasons for choosing one of London's markets for an IPO.
London offers a high quality investor base for emerging growth companies at a much lower cost than the United States. At a time when companies need to think creatively about how to finance their growth strategies, our panelists will discuss how U.S.-based growth companies can use a London IPO as an earlier entry point to the public markets to secure the capital they need and potentially as a stepping stone to a U.S. listing. Recent examples of U.S.-based companies that have come to market in London include life sciences companies such as Lunglife AI, Spectral MD, Renalytix and MaxCyte (the latter two subsequently completed U.S.IPOs with Stifel, with MaxCyte achieving a $1.3Bn valuation), and technology companies such as TinyBuild and Devolver Digital (the latter completed a $260M IPO with a $1Bn valuation in London in late 2021).
This event is intended for senior management of growth companies with equity valuations in the $50M – $2Bn range, as well as venture capital and growth private equity investors in such businesses.
Goodwin Capital Markets partner, Ariel White-Tsimikalis will join Brad Raymond, Global Head of Investment Banking, Stifel, Alex Price, Managing Director, European Technology Equity Capital Markets, Stifel, Chris Mayo, Head of Primary Markets, Americas, London Stock Exchange Group and Erik Lium, PhD and Chief Commercial Innovation Officer, Mount Sinai Health System for this panel discussion.